Friday, February 18th

Ander Urruticoechea, Onkologikoa, San Sebastián, Spain
16:00 - 16:20Pathological response as predictor of outcome after neoadjuvant chemotherapy
for operable breast cancer

Fraser W Symmans, University of Texas M.D. Anderson Cancer Center, Houston, USA
16:20 - 16:40PARP-1 inhibitors in early breast cancer
Andrew Tutt, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, UK
16:40 - 17:00Defining high-risk criteria for operable ER+/HER2- breast cancer
Joyce o´Shaughnessy, Baylor University Medical Center, Dallas, US
17:00 - 17:30Discussion
José Enrique Alés, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain
17:45 - 18:05Adjuvant endocrine treatment of premenopausal HR+/HER2- breast cancer patients
Olivia Pagani, European School of Oncology, University of Geneva and Lugano, Switzerland
18:05 - 18:25Sequencing therapies in metastatic HR-positive /HER2-negative breast cancer
Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain
18:25 - 18:45Advances in the neo/adjuvant treatment of triple negative breast cancer
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
18:45 - 19:15Discussion
Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain